drugset
drugset / Trial / NCT04841512

Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

NCT04841512 ↗

Phase 1/2 Withdrawn Xalud Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Preliminary safety and efficacy of XT-150 in the synovial capsule of osteoarthritic facet joints in the vertebra of the spine.

Timeline

Start
2021-10
Primary completion
2022-03-01
Completion
2022-03-01

Outcome

Outcome not reported

Stopped (Enrollment): “COVID - Lack of recruitment”

Drugs

EvaluationDrugModalityDoseRoute
Subject XT-150 Other / unclassified — Other

Indications

osteoarthritis, spine